Clinical Trial Evaluating DC/AML Fusion Cell Vaccination in AML Patients Who Achieve a Chemotherapy-Induced Remission
Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), Poorvi Somaiya(Beth Israel Deaconess Medical Center), Emma Breault(Beth Israel Deaconess Medical Center), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Jon Arnason(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Lynne Uhl(Hadassah Medical Center), Carol Delaney(Beth Israel Deaconess Medical Center), Ilene Galinsky(Dana-Farber Cancer Institute), Katarina Luptakova(Tesaro (United States)), Donald Küfe(Dana-Farber Cancer Institute), Richard M. Stone(Dana-Farber Cancer Institute), Baldev Vasir(Beth Israel Deaconess Medical Center), Daniel J. DeAngelo(Dana-Farber Cancer Institute), David P. Steensma(Harvard University), Dina Stroopinsky(Beth Israel Deaconess Medical Center), Heidi Mills(Beth Israel Deaconess Medical Center), Donna Neuberg(Otsuka (Japan)), James D. Levine(Beth Israel Deaconess Medical Center), Jeffrey I. Zwicker(Memorial Sloan Kettering Cancer Center)
Cited by 3
Related Papers
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k